Biomica CEO to Participate in an Industry Panel Discussion at Microbiome Connect USA 2022 Summit

Rhea-AI Summary

Biomica Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced its participation in the 7th Annual Microbiome Connect USA 2022 Summit on November 16-17, 2022, in Boston, MA. Dr. Elran Haber, Biomica's CEO, will join the panel discussion titled "Market Dynamics and Investment Landscape" on November 17 at 9:00 a.m. ET. The event aims to highlight drug development platforms utilizing microbiomes for disease prevention and treatment. Dr. Haber will also be available for one-on-one meetings during the conference.

REHOVOT, Israel , Nov. 14, 2022 /PRNewswire/ -- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be participating in an Industry panel discussion at the 7th Annual Microbiome Connect USA 2022 Summit taking place between November 16-17, 2022, in Boston, MA.

The conference is dedicated to showcasing the leading drug development platforms applying microbes, microbe modulators and microbial-derived components to prevent or treat human diseases or make medical diagnosis.

In attendance will be Dr. Elran Haber, CEO of Biomica. Dr. Haber will be part of an industry panel discussion titled, "Market Dynamics and Investment Landscape", taking place on November 17, 2022 at 9:00 a.m. ET.

Dr. Haber will be available for one-on-one meetings at the conference, and those interested should be in touch with the investor or public relations team.  

About Biomica
Biomica is an emerging biopharmaceutical company developing innovative microbiome-based therapeutics utilizing a dedicated Computational Predictive Biology platform (CPB), licensed from Evogene. Biomica aims to identify and characterize disease-related microbiome entities and to develop novel therapeutics based on these understandings. The company is focused on the development of therapies for antibiotic resistant bacteria, immuno-oncology, and microbiome-related gastrointestinal (GI) disorders. Biomica is a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN). For more information, please visit www.biomicamed.com.

Evogene Investor Contact: 
Kenny Green
Email: kenny.green@evogene.com
Tel: +1 212 378 8040 

Logo: https://mma.prnewswire.com/media/1015458/Biomica_Logo.jpg 
Logo: https://mma.prnewswire.com/media/890385/Evogene_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/biomica-ceo-to-participate-in-an-industry-panel-discussion-at-microbiome-connect-usa-2022-summit-301676909.html

SOURCE Biomica Ltd.

FAQ

What is Biomica's participation in the Microbiome Connect USA 2022 Summit?

Biomica will participate in the 7th Annual Microbiome Connect USA 2022 Summit on November 16-17, 2022, in Boston, MA.

When will Dr. Elran Haber speak at the conference?

Dr. Elran Haber will speak on November 17, 2022, at 9:00 a.m. ET.

What topics will be discussed at the Biomica panel session?

The panel session titled "Market Dynamics and Investment Landscape" will cover investment trends and market dynamics in microbiome-based therapeutics.

How can investors meet with Dr. Elran Haber during the summit?

Investors interested in one-on-one meetings with Dr. Elran Haber can contact the investor or public relations team.

What is the focus of Biomica's research?

Biomica is focused on developing microbiome-based therapeutics for antibiotic-resistant bacteria, immuno-oncology, and GI disorders.